Ongoing excellent outcomes with reduced toxicities following integration of molecular targeted therapies in pediatric anaplastic large cell lymphoma

Leuk Lymphoma. 2021 Aug;62(8):1995-1999. doi: 10.1080/10428194.2021.1894644. Epub 2021 Mar 8.

Authors

Peter McCarthy^{1

2}, John Harford¹, Aengus O'Marcaigh¹, Andrea Malone¹, Pamela Evans¹, Aoife Sills¹, Lorna Storey¹, Sean Rooney¹, David Betts¹, Maureen J O'Sullivan¹, Michael McDermott¹, Jonathan Bond^{1

2

3}, Amélie Trinquand^{1

3}, Owen P Smith^{1

2}

Affiliations

¹ National Children's Cancer Service, Children's Health Ireland at Crumlin, Dublin, Ireland.
² Systems Biology Ireland, School of Medicine, University College Dublin, Ireland.
³ National Children's Research Centre, Children's Health Ireland at Crumlin, Dublin, Ireland.

PMID: 33685326
DOI: 10.1080/10428194.2021.1894644

No abstract available

Publication types

Letter

MeSH terms

Anaplastic Lymphoma Kinase / genetics
Brentuximab Vedotin
Child
Humans
Longitudinal Studies
Lymphoma, Large-Cell, Anaplastic* / diagnosis
Lymphoma, Large-Cell, Anaplastic* / drug therapy
Molecular Targeted Therapy

Substances

Brentuximab Vedotin
Anaplastic Lymphoma Kinase